AVITA Medical, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AVITA Medical, Inc. (NASDAQ: RCEL; ASX: AVH) is a commercial-stage regenerative medicine company focused on therapeutic acute wound care solutions that accelerate skin healing and patient recovery. Founded in 1993 as Clinical Cell Culture in Perth, Western Australia, and restructured as AVITA Medical in 2008 with current headquarters in Valencia, California, the company develops and commercializes autologous cell-based technologies including its lead product, the RECELL System, an FDA-approved device for treating thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions; PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a branded collagen-based dermal matrix, all marketed primarily in the United States with distribution and operations extending to Japan, the European Union, Australia, the United Kingdom, and New Zealand. The RECELL System utilizes a patient's own skin sample processed at point-of-care to produce Spray-On Skin Cells via single-use RECELL GO cartridges and multi-use processing devices, enabling reduced donor site requirements and improved outcomes for burns, trauma, surgical wounds, and vitiligo in hospitals, burn centers, dermatology clinics, and plastic surgery settings. Recent developments include an exclusive multi-year development and distribution agreement with Regenity Biosciences announced in July 2024 for a novel collagen-based dermal matrix (branded Cohealyx), anticipated to receive FDA 510(k) clearance in late 2024 for U.S. commercialization alongside potential expansion to the EU, Australia, and Japan; an exclusive distribution partnership with Revolution Surgical Pty Ltd in November 2024 to reintroduce RECELL into Australia and New Zealand; FDA approval expansions for RECELL in vitiligo and soft tissue reconstruction boosting 2025 commercial revenues to $18.4 million in Q2 (up 21% year-over-year); and a name change from AVITA Therapeutics, Inc. to AVITA Medical, Inc. to better reflect its wound care focus.
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing
Avita Medical Q1 Earnings Call Highlights
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
AVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical Names Cary Vance as Chief Executive Officer
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
AVITA Medical to Announce First Quarter 2026 Financial Results
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
AVITA Medical, Inc. Investigated by the Portnoy Law Firm
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of “Hold” from Analysts
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know